Cisplatin, Docetaxel, and Nintedanib Before Surgery in Treating Patients With Previously Untreated Stage IB-IIIA Non-small Cell Lung Cancer

Inclusion Criteria: * Histologically or cytologically confirmed non-small cell lung cancer; patients with a suspected lung cancer are eligible, but pathology must be confirmed prior to initiating treatment on study; neuroendocrine carcinomas are not eligible; carcinomas with neuroendocrine differentiation are eligible * Stage IB (with a primary tumor \>= 4 cm), IIA, IIB, or IIIA (according to American Joint Committee on Cancer \[AJCC\] 7th edition); patients with stage IIIA must not have more than one mediastinal lymph node station involved by tumor * All patients must have lymph node evaluation of contralateral stations 2 and/or 4 to exclude N3 disease * The patient must be a suitable candidate for surgery, in the opinion of the treating physician * Eastern Cooperative Oncology Group (ECOG) performance status score 0-1 * Signed and dated written informed consent prior to admission to the study in accordance with International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH)-Good Clinical Practice (GCP) guidelines and to the local legislation Exclusion Criteria: * Prior systemic therapy or radiation therapy for treatment of the current lung cancer * Known hypersensitivity to the trial drugs or to their excipients * Centrally located tumors with radiographic evidence (CT or magnetic resonance imaging \[MRI\]) of local invasion of major blood vessels * Major injuries within the past 10 days prior to start of study …